Hirsutism Treatment

Hirsutism Treatment

Global Hirsutism Treatment Market to Reach US$4.2 Billion by 2030

The global market for Hirsutism Treatment estimated at US$3.0 Billion in the year 2023, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Hirsutism Medications, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Hirsutism Procedures segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$819.4 Million While China is Forecast to Grow at 8.0% CAGR

The Hirsutism Treatment market in the U.S. is estimated at US$819.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$867.0 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Key Trends and Drivers

Hirsutism, characterized by unwanted, male-pattern hair growth in women, is most commonly linked to an excess production of androgens or an increased sensitivity of hair follicles to androgens. Treatment for hirsutism aims to reduce hair growth and address any underlying hormonal imbalances, often associated with conditions like polycystic ovary syndrome (PCOS) or adrenal gland disorders. Common pharmacological treatments include anti-androgens such as spironolactone, which inhibit the effect of androgens on the hair follicle, and oral contraceptives, which can help regulate hormone levels and reduce androgen production. In addition to medication, physical hair removal techniques such as laser hair removal and electrolysis are widely used. These methods offer long-term solutions by targeting hair follicles and reducing hair growth directly at the site of application.

The field of hirsutism treatment has seen significant advancements in both drug therapies and hair removal technologies. The development of newer and more effective laser systems, such as diode lasers and alexandrite lasers, has improved the efficacy and safety of cosmetic treatments, making them suitable for a broader range of skin and hair types. Moreover, there is a growing trend towards integrating these treatments with pharmacotherapy to achieve better and more sustained results. On the pharmaceutical front, ongoing research is focused on more potent anti-androgens and novel agents that can target the hair growth cycle more effectively without significant side effects. This integrated approach helps in managing the symptoms more comprehensively, enhancing patient satisfaction and adherence to treatment protocols.

The growth in the hirsutism treatment market is driven by several factors, including increased awareness of the condition and more women seeking treatment for cosmetic and psychological reasons. The expansion of this market is also supported by innovations in both hormonal and non-hormonal treatments that offer improved results and safety profiles. Changing lifestyles and the rising incidence of PCOS and other endocrine disorders contribute to the increasing prevalence of hirsutism, further stimulating demand for effective treatments. Additionally, the global beauty and aesthetics industry`s growth provides a conducive environment for the adoption of advanced hair removal technologies, supported by an increase in disposable income and consumer spending on personal care. Market growth is also facilitated by the broadening of healthcare policies that cover treatments for conditions like PCOS, which indirectly support managing hirsutism.

Select Competitors (Total 36 Featured) -

• Corcept Therapeutics,Inc.
• Cosmo Pharmaceuticals NV
• Cutera Inc.
• GlaxoSmithKline, Plc
• Glenmark Pharmaceutical Inc
• Koninklijke Philips N.V
• Lumenis Ltd.
• Manus Aktteva Biopharma LLP
• Merck & Co. Inc.
• Nisim International Inc.
• Novartis International AG
• Pfizer Inc.
• ScinoPharm Taiwan Ltd
• Sciton, Inc.
• Teva Pharmaceuticals USA, Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.